Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)

Abstract

Introduction: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups. Methods: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state. Results: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0–21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3–33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response. Conclusion: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.

Original languageEnglish
Pages (from-to)132-143
Number of pages12
JournalEuropean Journal of Cancer
Volume182
DOIs
Publication statusPublished - Mar 2023

Bibliographical note

Funding
For the Dutch Melanoma Treatment Registry
(DMTR), the Dutch Institute for Clinical Auditing
foundation received a start-up grant from a governmental organisation, The Netherlands Organisation for
Health Research and Development (ZonMW, project
number 836002002). The DMTR is structurally funded
by Bristol Myers Squibb, Merck Sharpe & Dohme,
Novartis and Roche Pharma. Roche Pharma stopped
funding in 2019, and Pierre Fabre started funding the
DMTR in 2019. For this work, no funding was granted.

Publisher Copyright:
© 2023 The Author(s)

Fingerprint

Dive into the research topics of 'Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry'. Together they form a unique fingerprint.

Cite this